Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus
ConclusionThis thorough QT study demonstrated that therapeutic and supratherapeutic exposures of imeglimin did not induce a QT/QTc prolongation with a strong confidence as evidenced by the assay sensitivity.Trial registration number/dateNCT02924337/ October 5, 2016
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Avelox | Cardiology | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Electrocardiogram | Endocrinology | Heart | Moxifloxacin | Study